The non–small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth
factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors …

Mutations in the epidermal growth factor receptor (EGFR) make lung adenocarcinoma cells
sensitive to EGFR tyrosine kinase inhibitors (TKIs). Long-term cancer therapy may cause the …

The application of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
is limited by drug resistance in non-small cell lung cancer (NSCLC). Long non-coding RNAs …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used for
patients with EGFR-mutated lung cancer. Despite its initial therapeutic efficacy, most patients …

(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such
as gefitinib, has greatly affected clinical outcomes in non-small cell lung cancer (NSCLC) …

Our previous study demonstrated that long non-coding RNA (lncRNA) BC087858 could
stimulate acquired resistance to EGFR-TKIs in non-small cell lung (NSCLC) but the specific …

Objectives Despite initial responses to epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in EGFR mutant non-small cell lung cancer, patients invariably …

Simple Summary The introduction of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) has revolutionized the treatment of lung cancer. Nevertheless, TKI …

Simple Summary We attempted to identify target proteins and compounds that can be used
to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated EGFR …